Summary of Study ST002121
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001346. The data can be accessed directly via it's Project DOI: 10.21228/M8QX47 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST002121 |
| Study Title | Functional metabolic molecule were identified as novel therapeutic targets to facilitate gemcitabine treatment against pancreatic cancer (Tumor tissues metabolomics) |
| Study Summary | With the development of frontier technologies in system biology, traditional omics-drove phenotypic studies are insufficient to decipher the diseases. Therefore, for a thorough understanding of the molecular mechanisms of diseases to investigate novel drug targets, traditional phenotypic studies must be broken through to the functional exploration of molecules. Meanwhile, the intuitive role of small molecule compounds (metabolites) in pathogenesis, precision diagnosis and therapy are gradually recognized compared to macromolecules such as DNA, RNA and proteins. Therefore, we pioneeringly proposed Spatial Temporal Operative Real Metabolomics (STORM) strategy that established a relationship between metabolic phenotypes and functions to accurately character abnormal metabolisms and further identify operative functional molecules as novel therapeutic targets. Here, given the difficulty of pancreatic cancer (PC) treatment and the high resistance of clinical drugs, we were committed to explore new targets and drugs of pancreatic cancer from a small molecular functional perspective via STORM strategy. Fortunately, based on targeted metabolomics, we found that gemcitabine, one of the most effective clinical anti-PC drugs, served as a dual modulator that promote the accumulation of functional metabolic molecules in purine metabolism to activate down-streamed kinases. And the quantitative consequences of related enzymes annotated the unique molecular mechanisms of purine metabolism regulations by gemcitabine. Collectively, we broadened the cognitions of gemcitabine in tumor inhibition, providing potential strategies for treating PC with small molecules modification. Even more importantly, with the integration of multiple frontier technologies, the STORM strategy has proven to be well adapted to the phenotypic era of functional molecules devoted to innovate molecule mechanism annotation and therapeutic discovery. |
| Institute | Shanghai Center for Systems Biomedicine, Shanghai Jiaotong University |
| Last Name | Lu |
| First Name | Haitao |
| Address | 800 Dongchuan RD. Minhang District, Shanghai, |
| haitao_lu@sjtu.edu.cn | |
| Phone | 15221478139 |
| Submit Date | 2022-03-25 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | d |
| Analysis Type Detail | LC-MS |
| Release Date | 2022-04-20 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Treatment |
|---|---|---|
| SA204233 | M-1 | 2 times per week with 3 weeks consecutive respectively intraperitoneal injection with 0.2ml normal saline |
| SA204234 | M-7 | 2 times per week with 3 weeks consecutive respectively intraperitoneal injection with 0.2ml normal saline |
| SA204235 | M-6 | 2 times per week with 3 weeks consecutive respectively intraperitoneal injection with 0.2ml normal saline |
| SA204236 | M-3 | 2 times per week with 3 weeks consecutive respectively intraperitoneal injection with 0.2ml normal saline |
| SA204237 | M-4 | 2 times per week with 3 weeks consecutive respectively intraperitoneal injection with 0.2ml normal saline |
| SA204238 | M-5 | 2 times per week with 3 weeks consecutive respectively intraperitoneal injection with 0.2ml normal saline |
| SA204239 | G-7 | 2 times per week with 3 weeks consecutive respectively intraperitoneal injection with 25mg/kg gemcitabine in 0.2ml |
| SA204240 | G-6 | 2 times per week with 3 weeks consecutive respectively intraperitoneal injection with 25mg/kg gemcitabine in 0.2ml |
| SA204241 | G-1 | 2 times per week with 3 weeks consecutive respectively intraperitoneal injection with 25mg/kg gemcitabine in 0.2ml |
| SA204242 | G-2 | 2 times per week with 3 weeks consecutive respectively intraperitoneal injection with 25mg/kg gemcitabine in 0.2ml |
| SA204243 | G-4 | 2 times per week with 3 weeks consecutive respectively intraperitoneal injection with 25mg/kg gemcitabine in 0.2ml |
| SA204244 | G-5 | 2 times per week with 3 weeks consecutive respectively intraperitoneal injection with 25mg/kg gemcitabine in 0.2ml |
| Showing results 1 to 12 of 12 |
